Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1218)	12/8/2006 2:18:53 PM
From: DewDiligence_on_SI	Respond to of 3661

How many more shots on goal…? They’ve had a few shots at goal, but I’m not sure they’ve ever had a shot on goal. :-)

To: tuck who wrote (1218)	12/8/2006 2:48:30 PM
From: zeta1961	Read Replies (1) \| Respond to of 3661

OMG, Tuck..I was surfing quickly and I thought I ran into an old GNTA post!...My goodness, like the guest that wouldn't leave-g-

To: tuck who wrote (1218)	12/15/2006 7:34:35 PM
From: RockyBalboa	Respond to of 3661

FDA Rejects Genta Drug By Althea Chang TheStreet.com Staff Reporter 12/15/2006 10:59 AM EST Click here for more stories by Althea Chang Shares of drug developer Genta (GNTA - commentary - Cramer's Take - Rating) plummeted Friday after the company announced that regulators have deemed its proposed blood cancer treatment not approvable. Genta sank 18.7% to 56 cents in morning trading. The company was seeking clearance from the Food and Drug Administration to market Genasense for treatment of chronic lymphocytic leukemia, in combination with chemotherapy. We are keenly disappointed by this decision," said Genta's CEO, Dr. Raymond P. Warrell Jr. "We believe that Genasense has amply demonstrated its efficacy and safety in patients with relapsed and refractory CLL in a carefully designed and executed randomized clinical trial." The company said that while it decides on its next steps with U.S. regulators, it will continue seeking approval of Genasense in other countries for patients who have advanced cancer.